Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2007 2
2008 3
2009 2
2010 1
2013 1
2015 2
2016 4
2017 6
2018 5
2019 3
2020 4
2021 7
2022 6
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
Miklos DB, Abu Zaid M, Cooney JP, Albring JC, Flowers M, Skarbnik AP, Yakoub-Agha I, Ko BS, Bruno B, Waller EK, Yared J, Sohn SK, Bulabois CE, Teshima T, Jacobsohn D, Greinix H, Mokatrin A, Lee Y, Wahlstrom JT, Styles L, Socie G. Miklos DB, et al. Among authors: abu zaid m. J Clin Oncol. 2023 Apr 1;41(10):1876-1887. doi: 10.1200/JCO.22.00509. Epub 2023 Jan 6. J Clin Oncol. 2023. PMID: 36608310 Free PMC article. Clinical Trial.
High-dose chemotherapy for relapsed testicular germ cell tumours.
Chovanec M, Adra N, Abu Zaid M, Abonour R, Einhorn L. Chovanec M, et al. Among authors: abu zaid m. Nat Rev Urol. 2023 Apr;20(4):217-225. doi: 10.1038/s41585-022-00683-1. Epub 2022 Dec 7. Nat Rev Urol. 2023. PMID: 36477219 Review.
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. Kitko CL, et al. Among authors: zaid ma. J Clin Oncol. 2023 Apr 1;41(10):1864-1875. doi: 10.1200/JCO.22.00958. Epub 2022 Dec 2. J Clin Oncol. 2023. PMID: 36459673 Free PMC article. Clinical Trial.
A phase II study of buparlisib in relapsed or refractory thymomas.
Abu Zaid MI, Radovich M, Althouse S, Liu H, Spittler AJ, Solzak J, Badve S, Loehrer PJ Sr. Abu Zaid MI, et al. Front Oncol. 2022 Oct 18;12:891383. doi: 10.3389/fonc.2022.891383. eCollection 2022. Front Oncol. 2022. PMID: 36330484 Free PMC article.
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA. Sudha P, et al. Among authors: abu zaid mi. Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695. Clin Cancer Res. 2022. PMID: 35522533 Free PMC article.
48 results